- Market Research
- Stocks Research
- ETF Research
- Mutual Funds Research
- Options Research
- Bonds & Fixed Income Research
View our ETF quotes and sample our research offering.
Try our powerful tools to help compare investments and get ideas.
Find out about our industry leading research providers.
Kelly CRISPR & Gene Editing Technology ETF XDNA:NASDAQ
| Last Price | Today's Change | Today's Volume |  |  | |||
|---|---|---|---|---|---|---|---|
| $10.43 | +0.2393 (2.35%) | 728 Below Avg. | |||||
| As of close 07/01/2022 | |||||||
Fund Performance
Fund Strategy
The investment seeks to track the total return performance of the Strategic CRISPR & Gene Editing Technology Index.The adviser employs a “passive management” investment approach designed to track the total return performance of the index. The index is a rules-based index that consists of the stocks or corresponding depositary receipts of companies engaged in the creation, development, production, operation, provision, distribution, ownership, servicing, licensing, leasing or franchising of at least one of the DNA Modification Technology Business. The fund invests at least 80% of its net assets in DNA Modification Technology Companies. It is non-diversified.
Additional Information
Holdings: ETFs offer investors an interest in a portfolio of securities and other underlying assets and are therefore quite similar to mutual funds. One unique ETF feature is transparency, allowing investors to see the underlying portfolio securities on a daily basis.
| Details as of close 07/01/2022 | |
|---|---|
| Today's Open | $10.49 |
| Previous Close | $10.1907 |
| Day's Range | $10.30 - $10.49 |
| 52 Week Range | $8.69 - $14.99 |
| Closing NAV 06/30/2022 | $10.15 |
|---|---|
| Premium/Discount 06/30/2022 | 0.44% |
| Avg. Volume (10 Day) | 1,614 |
| Put/Call Ratio (1 Day) | -- |
| Put/Call Ratio (30 Day) | -- |
| Fund Profile | |||
| Fund Type | Exchange Traded Fund | Total Assets | $973.1K |
|---|---|---|---|
| Inception | 01/12/2022 | Gross Expense Ratio | 0.68% |
| Total Holdings | 24 | Net Expense Ratio | 0.68% |
Leveraged Exchange Traded ProductsLeveraged ETPs (exchange-traded products) typically use derivatives to attempt to multiply the returns of the underlying index each day. These securities trade much differently than other ETPs. They have the propensity to be more volatile and are inherently riskier than their non-leveraged counterparts. It is important to remember that these securities are generally designed for daily use only, and are generally not intended to be held overnight, because their returns over longer periods generally do not match the ETP’s multiple of the underlying index over those periods. These funds are not appropriate for most investors. Leveraged Closed-end FundsFunds that borrow money to purchase more assets in this way will generally move up more than the market when the market rises and move down farther than the market when the market falls. Bond funds that use leverage have the potential to increase the amount of income that they pay out, but at the cost of larger drops in value during a falling market. Leverage inherently increases the level of risk in a portfolio. | No | Portfolio Turnover | -- |
| For ETFs, this refers to the number of times the fund is long or short the index to explain its leverage factor. For example, -300 means that the ETF is short 3 times the index. | -- | ESG FundEnvironmental, Social, and Governance (ESG) is the industry term Schwab has chosen to use as an umbrella term to describe various investing approaches that consider not only traditional measures of risk and return, but environmental, social, and corporate governance (ESG) factors as well. Schwab uses ESG to broadly encompass ESG investing , but also investing approaches described as "values-based investing," "impact investing," "sustainable investing," and other approaches. An ESG product may apply ESG factors to its investment or governance processes in many different ways. A product that employs ESG strategies may choose to focus on one or more ESG factors, though an ESG product may also include securities that don't fit any ESG category. The information displayed utilizes the Morningstar "Sustainable Investment - Overall" datapoint. Click here to learn more about ESG at Schwab. 0222-22DC | No |
| Fund Company | Strategic | Active Semi-transparent Active Semi-transparent ETFsActive semi-transparent ETFs reveal full portfolio holdings only on a monthly or quarterly basis, not daily like traditional ETFs. There are different degrees of transparency as some firms will not disclose any daily holdings and others will reveal holdings daily, but shield certain positions and weights. Certain active semi-transparent ETFs may not be available for purchase or custody at Schwab. 1120-0XLE | No |
| Morningstar Category Specialty-health funds focus on the medical and health-care industries. Most invest in a range of companies, buying everything from pharmaceutical and medical-device makers to HMOs, hospitals, and nursing homes. A few funds concentrate on just one industry segment, such as service providers or biotechnology firms. | Health | Buffer ETFs provide investors with the opportunity to participate in the upside of an asset’s risk while giving investors some level of downside protection during a stated outcome period (typically one year). An upside return cap represents the maximum percentage of return an investor can achieve, and an investor will not participate in any excess returns above the cap. Buffer ETFs may limit an investor’s losses up to an ETF’s stated buffer limit; however, in the event of a decline in the underlying investments in excess of the buffer limit, the investor can experience those losses. Return cap and downside buffer levels for a Buffer ETF are established at the beginning of each outcome period and will likely differ from the prior outcome period. Buffer ETFs invest primarily in FLexible EXchange (“FLEX”) options to employ a structured or defined outcome strategy. 0721-13DB | No |
| Annualized Trend 1,5,10 Year | Annualized Returns | ||||
|---|---|---|---|---|---|
| Description | 1 Year | 5 Year | 10 Year | Inception 01/2022 | |
| XDNA Market Price | -- | -- | -- | -14.6% | |
| XDNA NAV | -- | -- | -- | -15.5% | |
| HealthMorningstar Category | -2.5% | +11.3% | +13.9% | -- | |
| MSCI ACWI NR USDBroad-Based Index | +7.3% | +11.6% | +10.0% | +6.3% | |
Datasource: Morningstar All performance periods are based on closing daily prices. | |||||
| View Performance | |||||
Top 10 Holdings as of 06/29/2022
Symbol | Description | % of Net Assets | Sector | YTD Chg. % | |
|---|---|---|---|---|---|
| BEAM | Beam Therapeutics Inc |
| Health Care | -50.1% | |
| NTLA | Intellia Therapeutics Inc |
| Health Care | -54.3% | |
| -- | CRISPR Therapeutics AG |
| Health Care | -12.3% | |
| EDIT | Editas Medicine Inc |
| Health Care | -52.6% | |
| ALLO | Allogene Therapeutics Inc |
| Health Care | -22.9% | |
| BLUE | bluebird bio Inc |
| Health Care | -57.2% | |
| SGMO | Sangamo Therapeutics Inc |
| Health Care | -42.9% | |
| TSVT | 2seventy bio Inc Ordinary Shares |
| Health Care | -48.0% | |
| VERV | Verve Therapeutics Inc |
| Health Care | -57.6% | |
| ABBV | AbbVie Inc |
| Health Care | +13.6% | |
| % of portfolio in top 10 holdings: 72.05% | |||||
| View Portfolio, All Holdings | |||||
Narrow your ETF choices
The new ETF Select List® — see our experts' top picks from a multitude of Schwab and third-party ETFs.
Watchlist
ETF Resource Center
Why are ETFs so popular?
Exchange traded funds have gained the favor of investors because of their low expense ratios, tax efficiency, diversification, trading flexibility and liquidity. They offer a lower relative cost alternative to other vehicles such as stocks and many mutual funds.
Where are ETFs traded?
What are the associated risks?
Do ETFs come with a prospectus?
Schwab's Financial and Other Relationships with certain ETFs
As your agreement for the receipt and use of market data provides, the securities markets (1) reserve all rights to the market data that they make available; (2) do not guarantee that data; and (3) shall not be liable for any loss due either to their negligence or to any cause beyond their reasonable control.
Performance data quoted represents past performance and does not indicate future results. Investment returns will fluctuate and are subject to market volatility, so that an investor's shares, when redeemed or sold, may be worth more or less than their original cost. Unlike mutual funds, shares of ETFs are not individually redeemable directly with the ETF. Shares are bought and sold at market price, which may be higher or lower than the net asset value (NAV). Current performance may be lower or higher. See the Performance tab for updated monthly returns.
Investors should consider carefully information contained in the prospectus or, if available, the summary prospectus, including investment objectives, risks, charges and expenses. You can request a prospectus by calling 800-435-4000. Please read the prospectus carefully before investing.
Investment returns will fluctuate and are subject to market volatility, so that an investor's shares, when redeemed or sold, may be worth more or less than their original cost. Unlike mutual funds, shares of ETFs are not individually redeemable directly with the ETF. Shares are bought and sold at market price, which may be higher or lower than the net asset value (NAV).
ETFs at Charles Schwab & Co., Inc. ("Schwab") which are U.S. exchange-listed can be traded without a commission on buy and sell transactions made online in a Schwab account. Unlisted ETFs are subject to a commission. Please see pricing guide for additional information. Schwab does not receive payment to promote any particular ETF to its customers. Schwab's affiliate Charles Schwab Investment Management, Inc. ("CSIM") serves as investment advisor to the Schwab ETFs, which compensate CSIM out of the applicable operating expense ratios. The amount of the fees is disclosed in the prospectus of each ETF.
Schwab receives remuneration from third-party active semi-transparent (also known as non-transparent) ETFs or their sponsors for platform support and technology, shareholder communications, reporting, and similar administrative services for third-party active semi-transparent ETFs available at Schwab. This fee will vary, but typically is an asset-based fee of 0.10% per annum of the assets held at Schwab. Neither Schwab's affiliate CSIM nor Schwab active semi-transparent ETFs pay a separate fee to Schwab for these services described, although CSIM reimburses Schwab, in its capacity as an affiliated financial intermediary of CSIM's, for Schwab's costs in providing certain professional, administrative, and support services for the Schwab ETFs.
Conditions Apply: Trades in ETFs which are U.S. exchange-listed are available without commissions when placed online in a Schwab account. Unlisted ETFs are subject to a commission. Trade orders placed through a broker will receive the negotiated broker-assisted rate. An exchange processing fee applies to sell transactions. All ETFs are subject to management fees and expenses. Please see pricing guide for additional information.
The Morningstar Rating™ for funds, or "star rating", is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods. Morningstar Ratings do not take into account sales loads that may apply to certain third party funds. The Overall Morningstar Ratings are derived from a weighted average of the risk adjusted performance figures associated with a Fund's 3-, 5-, and 10-year (if applicable) Morningstar Rating™ metrics.
Leveraged ETPs (Exchanged Traded Products, such a ETFs and ETNs), seek to provide a multiple of the investment returns of a given index or benchmark on a daily basis. Inverse ETPs seek to provide the opposite of the investment returns, also daily, of a given index or benchmark, either in whole or by multiples. Due to the effects of compounding and possible correlation errors, leveraged and inverse products may experience greater losses than one would ordinarily expect. Compounding can also cause a widening differential between the performances of an ETP and its underlying index or benchmark, so that returns over periods longer than one day can differ in amount and direction from the target return of the same period. Consequently, these ETPs may experience losses even in situations where the underlying index or benchmark has performed as hoped. Aggressive investment techniques such as futures, forward contracts, swap agreements, derivatives, options, can increase ETP volatility and decrease performance. Investors holding these ETPs should therefore monitor their positions as frequently as daily. To find out more about trading Leveraged and Inverse Products, please read Leveraged and Inverse Products: What you need to know.
Exchange-Traded Notes (ETNs) are distinct from Exchange-Traded Funds (ETFs). ETNs are debt instruments backed by the credit of the issuer and carry inherent credit risk. In some instances, ETNs can be subject to early redemption prior to maturity at the issuer’s discretion. Therefore, their value when called may be less than the market price that you paid or even zero, resulting in a partial, or total, loss of your investment. ETNs are not generally appropriate for the average investor. To find out more about ETNs, please read Exchange-Traded Notes: The facts and the risks.
The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of Morgan Stanley Capital International Inc. and S&P Global. GICS is a service mark of MSCI and S&P Global and has been licensed for use by Schwab.
The news sources used on Schwab.com come from independent third parties. Schwab is not affiliated with any of the news content providers. Schwab is not responsible for the content, and does not write or control which particular article appears on its website.
Charles Schwab Investment Advisory, Inc. ("CSIA") is an affiliate of Charles Schwab & Co., Inc. ("Schwab"). Schwab ETFs are distributed by SEI Investments Distribution Co. (SIDCO). SIDCO is not affiliated with The Charles Schwab Corporation or any of its affiliates.
Environmental, social and governance (ESG) strategies implemented by mutual funds, exchange-traded funds (ETFs), and separately managed accounts are currently subject to inconsistent industry definitions and standards for the measurement and evaluation of ESG factors; therefore, such factors may differ significantly across strategies. As a result, it may be difficult to compare ESG investment products. Further, some issuers may present their investment products as employing an ESG strategy, but may overstate or inconsistently apply ESG factors. An investment product's ESG strategy may significantly influence its performance. Because securities may be included or excluded based on ESG factors rather than other investment methodologies, the product's performance may differ (either higher or lower) from the overall market or comparable products that do not have ESG strategies. Environmental ("E") factors can include climate change, pollution, waste, and how an issuer protects and/or conserves natural resources. Social ("S") factors can include how an issuer manages its relationships with individuals, such as its employees, shareholders, and customers as well as its community. Governance ("G") factors can include how an issuer operates, such as its leadership composition, pay and incentive structures, internal controls, and the rights of equity and debt holders. Carefully review an investment product's prospectus or disclosure brochure to learn more about how it incorporates ESG factors into its investment strategy.
(0811-4794, 0813-5488, 1016-N2DC, 1017-7KFC, 1019-95HX, 0620-0EYJ, 0721-13DB, 0821-1ET8, 1221-1CZU, 0222-1024, 0222-22DC)